[Method for immunization against tuberculosis using BCG-M vaccine--a preparation with a reduced antigenic load]

Area of Science:

• Immunology
• Vaccinology
• Pediatric Infectious Diseases

Background:

• Standard BCG vaccine for tuberculosis immunization in newborns carries a risk of post-vaccinal reactions and complications.
• Optimizing vaccine composition is crucial for improving safety and efficacy in infant immunization programs.

Purpose of the Study:

• To investigate the feasibility of reducing the antigenic content of the Bacillus Calmette-Guérin (BCG) vaccine for newborn immunization.
• To develop and evaluate a novel BCG vaccine with reduced antigenic load, termed BCG-M.

Main Methods:

• Animal studies (guinea pigs, white mice) were conducted to compare the protective efficacy of reduced-dose versus full-dose BCG vaccine.
• Clinical trials were performed to assess the safety and effectiveness of the new BCG-M vaccine in infants.

Main Results:

• Experimental studies demonstrated that a reduced dose (0.025 mg) of BCG vaccine provided equivalent protection against tuberculosis compared to the full dose (0.5 mg).
• Clinical investigations showed that BCG-M significantly reduced the incidence of post-vaccinal reactions (lymphadenitis, ulceration) by threefold.
• The introduction of BCG-M led to an annual increase in infant immunization coverage against tuberculosis by 7-8%.

Conclusions:

• The development and implementation of BCG-M, a vaccine with reduced antigenic content, is a safe and effective strategy for infant immunization against tuberculosis.
• BCG-M offers improved safety profile and enhanced immunization coverage, contributing to better control of tuberculosis in pediatric populations.